Table 1.

Demographic and clinical data for study samples.

Study 1	Control	AD	MCI	Ctrl vs. AD
	n = 41	n = 43	n = 45	P c
Demographics
Male	11 (27%)a	16 (37%)	22 (49%)	0.43
Age (y)	67.5 ± 7.3b	65.9 ± 8.8	69.4 ± 6.6	0.36
CSF protein biomarkers
Aβ42 (pg/mL)	340 ± 137	203 ± 76	218 ± 90	<0.0001
t‐Tau (pg/mL)	44 ± 24	117 ± 70	76 ± 67	<0.0001
p‐Tau181 (pg/mL)	32 ± 15	75 ± 32	51 ± 25	<0.0001
t‐Tau/Aβ42	0.14 ± 0.09	0.64 ± 0.39	0.39 ± 0.33	<0.0001
APOE genotypes
Subjects with data (n)	n = 18	n = 13	n = 21	0.003
No ε4 alleles	11 (61%)	1 (8%)	10 (48%)
One ε4 allele	7 (39%)	8 (62%)	7 (33%)
Two ε4 alleles	0 (0%)	4 (31%)	4 (19%)

Study 2	n = 18	n = 50		P
Demographics
Male	8 (44%)	22 (44%)		1.00
Age (y)	61.2 ± 12.6	65.1 ± 9.3		0.24
CSF protein biomarkers
Aβ42 (pg/mL)	218 ± 112	143 ± 73		0.01
t‐Tau (pg/mL)	43 ± 30	114 ± 54		<0.0001
p‐Tau181 (pg/mL)	27 ± 16	56 ± 27		<0.0001
t‐Tau/Aβ42	0.23 ± 0.13	0.93 ± 0.53		<0.0001
APOE genotypes
Subjects with data (n)	n = 16	n = 40		0.19
No ε4 alleles	10 (63%)	15 (38%)
One ε4 allele	5 (31%)	17 (43%)
Two ε4 alleles	1 (6%)	8 (20%)

^a N (%) (all such values).

^bMean ± SD (all such values).

^c P‐values for control versus AD comparisons from t‐tests (continuous variables) or chi‐square tests (categorical variables).